229 related articles for article (PubMed ID: 33945142)
1. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
Thongsin N; Wattanapanitch M
Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
[TBL] [Abstract][Full Text] [Related]
2. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
[TBL] [Abstract][Full Text] [Related]
3. T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.
Gaykema LH; van Nieuwland RY; Lievers E; Moerkerk WBJ; de Klerk JA; Dumas SJ; Kers J; Zaldumbide A; van den Berg CW; Rabelink TJ
Stem Cells Transl Med; 2024 Jan; 13(1):69-82. PubMed ID: 37843402
[TBL] [Abstract][Full Text] [Related]
4. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system.
Thongsin N; Wattanapanitch M
Stem Cell Res; 2021 Oct; 56():102551. PubMed ID: 34628247
[TBL] [Abstract][Full Text] [Related]
5. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing.
Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA
Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591
[TBL] [Abstract][Full Text] [Related]
6. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
[TBL] [Abstract][Full Text] [Related]
7. Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived β2 Microglobulin Knockout Induced Pluripotent Stem Cells.
Zha S; Tay JC; Zhu S; Li Z; Du Z; Wang S
Cell Transplant; 2020; 29():963689720965529. PubMed ID: 33172291
[TBL] [Abstract][Full Text] [Related]
8. Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface.
Okutani Y; Abe K; Yamashita A; Morioka M; Matsuda S; Tsumaki N
Tissue Eng Part A; 2022 Jan; 28(1-2):94-106. PubMed ID: 34182799
[TBL] [Abstract][Full Text] [Related]
9. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
[TBL] [Abstract][Full Text] [Related]
10. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering.
Jang Y; Choi J; Park N; Kang J; Kim M; Kim Y; Ju JH
Exp Mol Med; 2019 Jan; 51(1):1-11. PubMed ID: 30617277
[TBL] [Abstract][Full Text] [Related]
11. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application.
Kitano Y; Nishimura S; Kato TM; Ueda A; Takigawa K; Umekage M; Nomura M; Kawakami A; Ogawa H; Xu H; Hotta A; Takasu N; Tsukahara M
Mol Ther Methods Clin Dev; 2022 Sep; 26():15-25. PubMed ID: 35755947
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
Dannenmann B; Nasri M; Welte K; Skokowa J
Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
[TBL] [Abstract][Full Text] [Related]
13. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
14. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
[TBL] [Abstract][Full Text] [Related]
15. Genome Editing of Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes to Model Genetic Ocular Diseases.
Getachew H; Chinchilla B; Fernandez-Godino R
Methods Mol Biol; 2022; 2549():321-334. PubMed ID: 34128206
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2).
Thongsin N; Suwanpitak S; Wattanapanitch M
Stem Cell Res; 2023 Sep; 71():103138. PubMed ID: 37343428
[TBL] [Abstract][Full Text] [Related]
17. Use of CRISPR/Cas ribonucleoproteins for high throughput gene editing of induced pluripotent stem cells.
Wang Q; Chear S; Wing K; Stellon D; Nguyen Tran MT; Talbot J; Pébay A; Hewitt AW; Cook AL
Methods; 2021 Oct; 194():18-29. PubMed ID: 33607266
[TBL] [Abstract][Full Text] [Related]
18. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
19. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.
Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG
J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557
[TBL] [Abstract][Full Text] [Related]
20. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
